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Abstract
Rationale Although newer interview methods such as
Structured Interview Guide for the Montgomery-Asberg
Depression Rating Scale (SIGMA; MADRS) with
audiotaping and Rater Applied Performance Scale (RAPS)
appraisal have been introduced to improve reliability of rat-
ings in antidepressant clinical trials, there is limited evidence
that these methods actually improve trial outcome.
Objective The objective of this study uis to evaluate outcome
in four similarly designed trials of two recently approved
antidepressants: two trials randomly used taped SIGMA in-
terviews with RAPS appraisal and two trials used traditional
semi-structured MADRS interviews.
Methods We reviewed data from patients who were screened
(N=243) and randomized (N=148), evaluating the magnitude
of change with placebo and antidepressants on mean total
MADRS score.
Results Depressed patients assigned to placebo in trials using
taped SIGMA interviews with RAPS appraisal had a signifi-
cantly larger MADRS change score (M=−11.5±12.7) com-
pared to patients assigned to placebo in trials using traditional
semi-structured interviews (−5.4±8.9; F(df=1.57)=5.58, p=
0.022). The error variance was also significantly larger in the
placebo arm of trials using SIGMA interviews (F=5.43, p=
0.023). Depressed patients assigned to antidepressants had
similar outcome in all of the four trials.
Conclusion The recently suggested modifications in
obtaining clinical data in antidepressant trials such as taped
SIGMA interviews with RAPS rating appraisals may in fact
result in a higher magnitude of placebo response and a lower
magnitude of antidepressant-placebo differences compared to
the traditional methods of collecting clinical data. These re-
sults were unexpected and indicate the necessity to test new
methods prospectively, nomatter how intuitively sensible they
seem, prior to their implementation.
Keywords Antidepressant clinical trials . Psychiatric
interviewmethods . Psychological evaluation . SIGMA .
MADRS . Levomilnacipran . Vilazodone
Introduction
It has been suggested that the variability and unpredictability
of response to antidepressants (25 to 60 % symptom reduc-
tion) and placebo (10 to 42 % symptom reduction) in antide-
pressant clinical trials (Khan et al. 2003) is related at least in
part to poor rating interview techniques. Specifically, it is
suggested that the traditional interview format is too loose
and not structured enough to obtain data that are valid and
similar across the different raters involved in a clinical trial
(Kobak et al. 2005, 2007; Engelhardt et al. 2006).
Furthermore, it is suggested that the interview technique of
a single rater may vary from interview to interview throughout
a trial. Kobak et al. (2007) and Engelhardt et al. (2006) suggest
that raters in antidepressant clinical trials are therefore prone to
low levels of reliability. Also, there may be rater bias of
inflating the entry scores to make depressed patients eligible
to enter into a trial.
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The idea that an increase in the reliability of ratings may
enhance antidepressant-placebo differences (Lipsitz et al.
2004) was supported in a retrospective study by Cogger
(2007). He evaluated the quality of a subsample of taped
interviews from a paroxetine trial and noted that the effect
size between antidepressant and placebo was much larger if
the interviewers adhered to a specific format, asked the same
questions, and took adequate time to get the best answers.
Based in part on the concept that the reliability of ratings in
antidepressant trials could affect outcome, a fewmodifications
in the conduct of recent antidepressant clinical trials were
suggested: “rating the raters” (Engelhardt et al. 2006), Rater
Applied Performance Scale (RAPS) appraisal (Lipsitz et al.
2004), and a Structured Interview Guide for the Montgomery-
Asberg Depression Rating Scale (SIGMA; MADRS)
(Williams and Kobak 2008; Montgomery and Asberg 1979).
Audiotaping or videotaping interviews that are conducted
either remotely (central raters) or at the investigative site (local
raters) have been used to verify adherence to the modified
interview formats.
Kobak et al. (2010) reported that the “central raters” trained
in these structured interview techniques noted a lower magni-
tude of placebo response compared to the “local raters” who
conducted interviews in person at the trial site. The authors
attributed this difference in outcome to more reliable ratings
by the “central raters.” However, three recent reports have
challenged the concept that rating interview modifications
have the intended effect of increasing antidepressant-placebo
differences.
Oren et al. (2008) reported results from a trial of an inves-
tigational medication versus escitalopram and placebo using
centralized raters who determined patient eligibility and
assessed the primary outcome measure. The trial reported by
Oren et al. used raters who were not based at the study site,
who remotely interviewed patients via a video screen. The
remote raters were unaware of the stage of the study the
patient was in and the raters changed for each visit. These
modifications were done to achieve uniformity of ratings,
enhance reliability of ratings, and minimize rater bias. The
authors reported no significant difference in outcome between
placebo and escitalopram, and the results for the investiga-
tional medication were significantly worse than for placebo
(p=0.04).
More recently, Targum et al. (2013) reported results from a
study evaluating trial outcome differences based on the meth-
od of rating: “central raters” that conducted interviews via a
videoconference interview versus local site raters. A signifi-
cant difference indicating superiority of combination
(buspirone plus melatonin) treatment versus placebo was re-
ported on the IDSc30 (Rush 2000) for the site-based ratings
(p=0.030), whereas the centralized ratings did not detect this
difference (p=0.124) (details reported in Table 3 of the
Targum et al. publication).
Lastly, Khan et al. (2014) evaluated outcome of three
clinical trials that used SIGMA interview ratings that were
audiotaped and were either conducted or appraised remotely
versus four clinical trials that used traditional semi-structured
MADRS interviews. Our primary focus was on the outcome
with the placebo groups because not all of the agents were
approved for the treatment of depression by the US Food and
Drug Administration (FDA). We found a larger magnitude of
change in the placebo group among trials that used taped
SIGMA interviews with remote scoring or appraisal, and we
also found significantly more variability in the outcome with
placebo in the subset of trials using these newer interview
methods.
Given this background, we undertook the current study to
further assess the effect of rating interview format on clinical
trial results. We systematically reviewed data from the antide-
pressant and placebo arms of four of the antidepressant clin-
ical trials that were included in our previous study. All of the
trials used antidepressants that have been approved by the US
Food and Drug Administration.
Most importantly, the trials were all conducted by the same
pharmaceutical company and all used similar clinical trial
design. The primary difference in the conduct of the trials
was that two of the four trials used SIGMA interviews that
were taped to obtain MADRS ratings and the ratings from
these trials were subject to outside RAPS appraisal, whereas
the other two trials used traditional semi-structured MADRS
interviews. The choice of the evaluation method was random-
ly chosen by the sponsoring company. Our evaluation focused
on the outcome in the antidepressant and placebo arms in each
subset of trials.
We hypothesized that the antidepressants trials that used
the newer patient evaluation techniques would result in a
lower magnitude of differences between antidepressants and
placebo compared to the traditional patient interview tech-
niques. Furthermore, we hypothesized that such a difference
would be related to the magnitude of change among depressed
patients assigned to placebo.
Methods
Background
Of the 12 antidepressant trials conducted at the Northwest
Clinical Research Center (NWCRC) between 2009 and 2011,
only four were suitable for the current study. The other eight
trials included investigational antidepressants that have not
been approved or enrolled depressed patients who were
treatment-resistant. The other trials conducted at NWCRC
during this time were therefore not suitable for inclusion in
the study.
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All of the four included trials were sponsored by the same
pharmaceutical company with nearly identical study design
aside from the interview method. For two of the trials, the
sponsoring company randomly chose to use interview modi-
fications including site-based SIGMA interviews that were
audiotaped and appraised for RAPS adherence by outside
interview monitors. The other two trials were conducted using
the traditional method of interviews to obtain data for
MADRS scores. The NWCRC had no input as to which
method was used by the company.
Although the subset of trials that used taped SIGMA inter-
views with outside RAPS appraisal used newer rating
methods, the site-based raters that conducted the ratings were
the same for each subset of trials. Each of the site-based raters
had more than 2 years of experience participating in clinical
trials, and the raters each had a Master’s Degree in Clinical
Psychology or related field. All of the site raters also complet-
ed the study-specific rater training for each study in which
they participated.
Of the four trials included in our study, three of the trials
evaluated the recently approved agent levomilnacipran and
one of the trials was a placebo-controlled phase IV study of
vilazodone which was approved in 2011. The SIGMA inter-
views that were taped with outside RAPS appraisal were used
during two of the levomilnacipran trials, and traditional semi-
structured MADRS rating methods were used in the third
levomilnacipran trial and the vilazodone trial.
The primary outcome variable for each of the trials was the
change in MADRS score from baseline to final visit based on
the depression scale scores of the site-based raters. The central
appraisal was done post hoc and the appraisals were issued
shortly after the site-based ratings were completed to encour-
age conformity with SIGMA style throughout the trials.
Characteristics of the trials and demographics of the patients
The fact that clinical trial design characteristics are associated
with clinical trial outcome is well documented. Factors such as
the baseline severity of depression (Joyce and Paykel 1989;
Khan et al. 2002) are associated with the trial outcome and
may influence the proportion of patients that qualify for a trial.
A lower probability of being assigned to placebo may increase
patient expectations for improvement, resulting in a higher
placebo response (Papakostas and Fava 2009; Rutherford
et al. 2009; Sinyor et al. 2010).
We therefore critically evaluated the trial characteristics
and patient demographics of the trials using the taped
SIGMA interviews with RAPS appraisals as compared to
the trials using the traditional semi-structured MADRS inter-
views prior to comparing outcome of the trials. Each of the
trials recruited and enrolled patients diagnosed with major
depressive disorder. Patients diagnosed with treatment-
resistant depression defined as a failure of two adequate
antidepressant treatment trials during their lifetime were ex-
cluded from each of the four trials.
All four trials used a randomized, parallel group, double-
blind, placebo-controlled design. The visitation schedule was
also identical among the four trial including a pre-
randomization (“baseline”) visit as well as visits at weeks 1,
2, 4, and 6 with the final MADRS rating being assessed at the
week 8 visit. As shown in Table 1, all of the trials were of
8 weeks duration. A similar number of patients were screened
for study enrollment in trials using the different rating
methods (taped SIGMA interview trials with RAPS appraisal,
N=120; traditional semi-structured MADRS interview trials,
N=123). Of the patients that presented for screening, there
were no significant differences in age, sex, or racial charac-
teristics between the two groups of trials.
However, there were some significant differences in the
two sets of trials as described below. The two trials using the
SIGMA interviews that were audiotaped and appraised had a
higher entry criterion for pre-randomization severity of de-
pression symptoms at the time of randomization. These two
trials required the total MADRS score to be 30 or higher,
whereas the two trials using the traditional interview tech-
niques required the total MADRS score to be 26 or higher.
The screen fail rate of 48 % was significantly higher in
trials using taped SIGMA interviews with outside RAPS
appraisal compared to the screen fail rate of 31 % in the trials
using traditional semi-structured interviews (p<0.001). This
resulted in fewer patients being enrolled in the trials using the
newer interview methods (N=63) compared to the trials using
the traditional interview methods (N=85).
The higher pre-randomization score requirement was also
likely related to the higherMADRS scores of patients enrolled
in the SIGMA trials (M=37±4) as compared to those enrolled
in the trials using traditional semi-structured MADRS inter-
view methods (M=32±3; p=0.008). Lastly, the placebo risk
was not significantly different in the two types of study as
shown in Table 1. Of the patients enrolled in the trials using
SIGMA interviews, 22 were assigned to placebo and 41 were
assigned to antidepressants (35 % chance of receiving place-
bo). Of the trials conducted using traditional interviews, 37
were assigned to placebo and 48 were assigned to antidepres-
sants (44 % chance of receiving placebo).
Aside from the higher baseline severity of depression in the
trials using the SIGMA interviews with audiotaping and out-
side RAPS appraisal, there was very little difference in either
the patient population or the design and conduct of the trials.
We therefore considered it appropriate to control for the base-
line severity of depression by entering it as a covariate in all of
our analyses. This allowed for us to primarily analyze any
difference in outcome that may have been associated with
rating methodology as this design feature was the primary
difference in conduct of the trials and was the focus of our
evaluation.
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Analysis of data
All of the data for analysis was from one site (NWCRC) only.
The results of the overall studies are being presented and
published by the sponsoring pharmaceutical company.
Our first analysis was an ANOVA that evaluated the outcome
for patients assigned to placebo in the trials using the SIGMA
ratings that were taped with outside RAPS appraisal versus the
trials that used traditional semi-structured MADRS interviews.
We entered the last observation carried forward (LOCF)MADRS
score as the dependent variable with the pre-randomization sever-
ity of depression as a covariate. The style of rating used to conduct
the interview was the independent variable.
The next analysis focused on the outcome for patients
assigned to antidepressants who were enrolled in the trials using
taped SIGMA ratings with outside RAPS appraisal compared to
outcome for patients assigned to antidepressants who were en-
rolled in the trials using traditionalMADRS interviews.We again
used an ANOVA with the last observation carried forward en-
tered as the dependent variable and again controlled for the pre-
randomization severity of depression by entering it as a covariate.
For each analysis, we evaluated the equality of error vari-
ance in the two subsets of trials using Levene’s test of equality
of error variances. All of the analyses were conducted using
SPSS versions 19.0.
Lastly, we evaluated the overall outcome with antidepressant
versus placebo in each subset of trials. We again used two
ANOVAs for this analysis: the first was for the SIGMA trials
with taping and outside appraisal with the second ANOVA
evaluating the trials using traditional, semi-structured interviews.
The dependent variablewas the LOCFMADRSobservationwith
the patient assignment to antidepressants or placebo being the
independent variable. We again controlled for the baseline sever-
ity of depression by entering it as a covariate in both analyses.
Results
The mean MADRS scores at each study visit among patients
included at NWCRC and assigned to placebo and antidepres-
sants based on the rating method used in the trials are shown
as Table 2. The patients that were assigned to placebo partic-
ipating in trials using taped SIGMA interviews with outside
RAPS appraisal had a significantly higher magnitude of pla-
cebo response (MADRS change score of −11.5±12.7) com-
pared to the patients assigned to placebo that participated in
the trials using traditional semi-structured interviews
(MADRS change score of −5.4±8.9; F(df=1.57)=5.58, p=
0.022). There was also significantly greater error variance in
LOCF evaluations of patients assigned to placebo in the trials
using SIGMA methods (F=5.43, p=0.023).
There were no significant differences in change score in the
antidepressant arm of the trials. The MADRS change score in
the patients assigned to antidepressants in the trials using
taped SIGMA interviews with outside RAPS appraisal was
−13.5±9.4 compared to the antidepressant change score of
Table 1 Trial characteristics and patient demographics of those screened and enrolled in clinical trials of recently approved antidepressants
levomilnacipran (trials 1, 2, and 4) and vilazodone (trial 3) based on patient rating method
Trials using SIGMA interviews with tape
recording RAPS appraisal
Trials using traditional semi-structured
depression interviews
Probabilitya
Trial 1 Trial 2 Totals (trials 1 and 2 ) Trial 3 Trial 4 Totals (trials 3 and 4)
Trial duration 8 8 – 8 8 – –
No. of patients screened 79 41 120 79 44 123 –
Mean age (±SD) 39 (12) 39 (14) 39 (13) 38 (12) 41 (14) 39 (13) 0.95
Female (%) 49 56 52 47 52 49 0.65
Caucasian (%) 68 81 73 70 64 68 0.39
No. of patients randomized 39 24 63 53 32 85 –
Screen fail rate 51 41 48 32 27 31 0.008
Mean pre-randomization score (±SD) (MADRS) 37 (5) 36 (4) 37 (4) 32 (3) 32 (3) 32 (3) <0.001
Placebo exposure risk 50 % 25 % 35 % 50 % 33 % 44 % 0.29
Early discontinuation (%) 26 % 13 % 21 % 17 % 31 % 22 % 0.80
Data presented are from a single research center
Bolded italicized values indicate a significant difference between trials using the SIGMA interviews as compared to the trials using traditional non-
SIGMA MADRS interviews such that the screen fail was significantly higher in trials 1 and 2 with the mean pre-randomization score also being
significantly higher in trials 1 and 2.
SIGMA Structured Interview Guide for the Montgomery-Asberg Depression Rating Scale, RAPS Rater Applied Performance Scale, MADRS
Montgomery-Asberg Depression Rating Scale
a Probability values were determined by chi-square test of independent samples t test
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patients participating in the trials using traditional semi-
structured interviews of −13.7±10.3. There was also no sig-
nificant difference in error variance in the antidepressant arms
of the trials using SIGMA interviews with outside RAPS
appraisal as compared to the trials using traditional interviews
(F=2.41, p=0.12).
The comparisons of antidepressant and placebo within the
subsets of trials are shown as Fig. 1a, b. Figure 1a is a scatter
plot showing the relationship between MADRS pre-
randomization score and MADRS change score with antide-
pressants and placebo in the trials using SIGMA interviews that
were taped with outside appraisal. After controlling for pre-
randomization severity of depression, there was not a signifi-
cant difference in MADRS change score for antidepressants
(−13.5±9.4) compared to placebo (−11.5±11.5; F(df=1.61)=
0.504, p=0.481). In these trials, the placebo arm had a larger
error variance compared to the drug arm (F=5.34, p=0.024).
Figure 1b is a scatter plot showing the relationship between
MADRS pre-randomization score and MADRS change score
with antidepressants and placebo in the trials using traditional
semi-structured interviews. The MADRS change score with
antidepressants (−13.7±10.3) was significantly larger than the
MADRS change score with placebo (5.4±8.9; F(df=1.83)=
14.5, p<0.001). The error variance tended to be larger in the
antidepressant group (F=3.7, p=0.058).
Discussion
The aim of this study was to evaluate the outcome among
patients assigned to antidepressants and placebo in a group of
four similarly conducted antidepressant clinical trials of two
Table 2 Change over timewith antidepressants and placebo in two trial using SIGMA interviewswith taping and outside RAPS appraisal (trials 1 and 2)
compared to two similarly conducted trials using traditional semi-structured MADRS interviews (trials 3 and 4).
Placebo Antidepressant
Visit SIGMA ratings
(trials 1 and 2, N=20)
Traditional ratings
(trials 3 and 4, N=34)
Taped SIGMA ratings
(trials 1 and 2, N=32)
Traditional ratings
(trials 3 and 4, N=40)
Baseline 36.9±4.8 31.8±3.7 36.6±4.3 31.0±3.0
Week 1 32.3±6.8 30.7±4.4 32.1±4.5 28.7±4.5
Week 2 30.5±8.1 29.2±5.0 28.5±6.1 25.2±6.4
Week 4 25.7±9.6 26.7±8.0 23.1±8.0 22.1±8.0
Week 6 23.3±11.9 25.9±9.9 21.8±10.1 16.9±9.0
LOCF 23.5±13.4a 26.0±10.5a 21.1±9.3 15.0±9.3
Change score −11.5±12.7b −5.4±8.9b −13.5±9.4 −13.7±10.3
SIGMA Structured Interview Guide for the Montgomery-Asberg Depression Rating Scale, RAPS Rater Applied Performance Scale, LOCF Last
Observation Carried Forward
a After controlling for baseline severity of symptoms, there was a significant difference in LOCF score in the placebo arm (F(df=1.57)=5.58, p=0.022)
with the taped SIGMA trials with outside appraisal having significantly greater change score with placebo compared to the trials using traditional non-
SIGMA ratings. There was also significantly more error variance at the LOCF visit in trials using SIGMA ratings (F(1.57)=5.43, p=0.023).
b The placebo change score was significantly greater in the trials using SIGMA ratings, t(df=57)=2.2, p=0.034 and the variance with placebo was





















































Fig. 1 a Scatter plot of MADRS baseline and pre-randomization scores in
trials using SIGMA interviews that are taped with RAPS appraisal from
outside reviewers. There was no significant difference in outcome for patients
assigned to antidepressant versus placebo (F(df=1,61)=0.5, p=0.48). b
Scatter plot of MADRS baseline and pre-randomization scores in trials using
traditional non-SIGMAMADRS interviews. TheMADRS change scorewas
significantly higher for patients assigned to antidepressants versus placebo
(F(df=1.83)=14.48, p<0.001). SIGMA Structured Interview Guide for the
Montgomery-Asberg Depression Rating Scale, RAPS Rater Applied Perfor-
mance Scale,MADRSMontgomery-Asberg Depression Rating Scale
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recently approved antidepressant medications; two of the trials
randomly used the newer structured SIGMA format followed
by a RAPS appraisal from independent reviewers with two
trials using traditional semi-structured MADRS interviews.
All of the analyses included only data from depressed patients
who participated at a single site (NWCRC) as part of the four
large multicenter trials.
Our finding supported our hypothesis that the antidepres-
sants using the newer interview techniques would have a
lower magnitude of antidepressant-placebo differences, large-
ly due to a larger magnitude of change with placebo rather
than magnitude of change with antidepressants. This finding
further supports our earlier finding (Khan et al. 2014). Our
study is the first to evaluate how the structured interview
methods with taping of the patients and outside appraisal of
the clinical trial raters may actually impact outcome of pivotal
antidepressant trials as the only antidepressants that were
evaluated in our study have been shown to be effective in
multiple antidepressant clinical trials that have undergone
FDA review.
These results are consistent with the results of the Oren
et al. (2008) trial and those of Targum et al. (2013) who both
reported negative findings in trials using some of the recently
introduced methods of rating in antidepressant clinical trials.
Oren et al. found that central raters were unable to distinguish
antidepressants from escitalopram in a trial of an investiga-
tional antidepressant that has yet to be approved, whereas
Targum et al. reported that the site raters were able to detect
a difference in combination therapy versus placebo that the
centrally based raters could not detect.
On the other hand, our findings do not support the findings
of Cogger (2007) or Kobak et al. (2010) among the published
trials that have usedmodified interview techniques of different
varieties to increase the reliability of depression ratings. In
other words, although it is implied that greater reliability and
homogeneity of ratings will result in a better outcome, we
found that newer techniques resulted in a larger and more
variable placebo response in pivotal approval trials that were
part of drug development programs.
In this context, it is important to note that in the past 5 years
far more trials than the four included in our study have used
various modifications to depression interview techniques.
These modifications replace the traditional semi-structured
MADRS interviews with methods including SIGMA, both
central and local raters, or just central raters, and either
audio- or videotaping. The data from the majority of these
trials have not been systematically presented or published.
Given this fact, the results of our study cannot be considered
definitive until the data from these trials are fully available in
the public domain. Also, our study does not evaluate the role
of centralized ratings compared to site ratings.
In trying to understand our finding, we asked several raters
and patients about their rating experiences. In describing her
experience with the structured and appraised interviews, one
rater said, “You are aware that your adherences to the exact
language of the form as well as your assessment skills are
being monitored. Of course, the interviewer begins to focus
more on the details of the interview form and her own perfor-
mance and attention is less available to focus on the patient.
What is lost is the level of information that comes from a more
global perception of the patient presentation, including non-
verbal cues.”
Another rater had this to say about the SIGMA ratings
with audiotaping and RAPS appraisal, “These are ques-
tion and answer sessions and do not get into an in-depth
exploration of the patient’s world that is unique to the
individual. Also, I feel that patients feel that they are
being scrutinized for good behavior and have to present
themselves in the best light and are reluctant to criticize
their experience. Simply put the patients become actors
and seem to perform for the ratings.”
As a rule, patients were reluctant to sign up for the taped
sessions and expressed preference for studies not requiring
audiotaping. As one patient said, “I feel like big brother is
watching and I have to behave myself”. At the end of taped
sessions several patients made statements like, “the tape is off,
right? Now, we can talk about anything I want, right?”
An additional incongruent fact in our study was that unlike
the case in many previous studies, severity of pre-
randomization depressive symptoms did not influence the
outcome of the trial (Joyce and Paykel 1989; Khan et al.
2002, 2005). The antidepressant trials using the SIGMA in-
terview technique, audiotaping, and RAPS review had higher
pre-randomization scores, but a smaller magnitude of
antidepressant-placebo differences.
These data raise concern about modifying standard psy-
chiatric interview techniques and trial designs based on
ideas that may have face validity, but have not been tested.
This is a common practice in depression trials, and it may
have led to many instances of type II errors. Specifically, if
only modified interview formats had been used, it is pos-
sible that neither vilazodone nor levomilnacipran would
have been approved by the US FDA. Thus, the recently
suggested potpourri of antidepressant clinical trial design
modifications should only be implemented if sufficient
prospective data exist.
In conclusion, the recently suggested modifications in
obtaining clinical data in antidepressant trials such as
SIGMA interviews that are taped with ratings appraised by
RAPS feedback may in fact result in a higher magnitude of
placebo response and a lower magnitude of antidepressant-
placebo differences compared to the traditional methods of
collecting clinical data. These results were unexpected and
indicate the necessity to test new methods prospectively, no
matter how intuitively sensible they seem, prior to their im-
plementation. Thus, caution is warranted in how clinicians
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interpret data from failed or negative antidepressant clinical
trials.
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